Serial entrepreneur brings 30 years of healthcare leadership
Atlanta, GA, February 26, 2019 — Oncology Analytics, a leading technology-enabled service company which provides health plans, providers and patients with an evidence-based, analytics focused approach to utilization management purpose-built for oncology, has announced the appointment of Michael Weintraub to the company’s Board of Directors.
“We are excited to welcome Michael to our Board of Directors and look forward to both collaborating and benefitting from his vast experience in healthcare data analytics,” said Rick Dean, Oncology Analytics’ CEO. “Michael’s years of successful leadership in the healthcare industry, specifically with digital health innovation and analytics, aligns perfectly with our mission to use data, analytics, and evidence-based medicine to impact patient access and options for cancer treatment.”
Weintraub was most recently managing partner of Optum Ventures, a leading health services company focused on digital health innovation. He also co-founded and served as CEO of Humedica, a pioneer and leader in the field of population health management and big data. In 2013, Humedica was acquired by UnitedHealth Group, and he broadened his role within the company to become president and CEO of Optum Analytics. Before launching Humedica, he served as senior managing director at Leerink Partners, a leading healthcare investment bank. He was also president and CEO of PHARMetrics, a healthcare informatics company, which was acquired by IMS Health, now IQVIA, in 2005. He received his MBA from Harvard Business School and earned his bachelor’s degree in economics from Brandeis University.
“The work and insights that Oncology Analytics provides is a game changer in specialty drug management,” said Weintraub. “Its unique patient-first strategy, which ensures cancer patients receive the best possible cancer treatment, is the type of positive disruption needed in oncology benefits management.”
Oncology Analytics employs technology, analytics, and deep oncology experience to ensure patients get the right treatment, at the right time, at the right costs. It provides health plans with extensive expertise that ensures the use of high-cost anti-cancer therapies are based on science and evidence-based protocols. It’s goal is to help drive the healthcare industry to invest in better predictive analytics that measure the efficacy, toxicity, and affordability of treatment options.
About Oncology Analytics
Oncology Analytics, Inc. provides health plans, providers and patients with an evidence-based, technology-driven approach to utilization management, which is purpose-built for oncology. Used by physicians to support over 3.5 million health plan members in the US and Puerto Rico, the Oncology Analytics e-Prior Authorization platform is updated daily to accurately reflect more than 6,000 oncology treatment protocols for anti-cancer treatment across all cancer types and stages, including chemotherapy, radiation therapy, precision medicine, targeted therapy, and supportive care. The company’s real-world evidence analytics is based on tens of thousands of annual chemotherapeutic cases.